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Abstract
Genistein is an isoflavone found in soy, and its chemo-preventive and -therapeutic effects have been well established from
in vitro studies. Recently, however, its therapeutic actions in vivo have been questioned due to contradictory reports from
animal studies, which rely on rodent models or implantation of cell lines into animals. To clarify in vivo effects of genistein in
advanced prostate cancer patients, we developed a patient-derived prostate cancer xenograft model, in which a clinical
prostatectomy sample was grafted into immune deficient mice. Our results showed an increased lymph node (LN) and
secondary organ metastases in genistein-treated mice compared to untreated controls. Interestingly, invasive malignant
cells aggregated to form islands/micrometastasis only in the secondary organs of the genistein-treated groups, not in the
untreated control group. To understand the underlying mechanism for metastatic progression, we examined cell
proliferation and apoptosis on paraffin-sections. Immunohistological data show that tumors of genistein-treated groups
have more proliferating and fewer apoptotic cancer cells than those of the untreated group. Our immunoblotting data
suggest that increased proliferation and metastasis are linked to enhanced activities of tyrosine kinases, EGFR and its
downstream Src, in genistein-treated groups. Despite the chemopreventive effects proposed by earlier in vitro studies, the
cancer promoting effect of genistein observed here suggests the need for careful selection of patients and safer planning of
clinical trials.
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed
noncutaneous malignancy among North American men [1]. In
2009, about 192, 280 new cases of prostate cancer were diagnosed,
and 27, 360 deaths were reported in the United States, ranking it
second highest in mortality after lung cancer [2]. Compared to the
USA, the incidence and mortality rates of prostate cancer are
considerably lower in Asia [3,4,5]. Immigration studies have
shown that Asians, who have adopted the western diet after
immigration to the USA, had a significantly higher prostate cancer
incidence than natives in Asian countries [6,7]. Among many
dietary differences between North America and Asia, the
difference in soy consumption is exceptional. It is estimated that
Asians consume 20–50 times more soy-based foods per capita
compared to North Americans [8]. Previous epidemiological
reports have indicated an inverse correlation between soy
consumption and PCa risk, suggesting soy’s chemopreventive
effects [9]. The primary active component of soy is an isoflavone
called genistein (4,5,7-trihydroxyisoflavone) [10,11,12,13]. Due to
similar molecular structure to estradiol, genistein is known to
exhibit weak estrogenic activity by binding to the estrogen receptor
(ER) and thus modulating estrogen-regulated gene transcription in
target organs [14,15].
The anticancer effects of genistein have been well studied in vitro
and reported in several cancer cell lines including leukemia, lung,
prostate and breast [16,17,18,19]. Data from earlier studies
demonstrate that genistein has a wide spectrum of biological
effects, which include: induction of cell differentiation and
apoptosis [17,18,19,20], inhibition of cell growth [19,21,
22,23,24], and abrogation of signal transduction pathways
[25,26,27]. Genistein, thus, has attracted a considerable amount
of attention in cancer research especially for its inhibitory action
on protein tyrosine kinase (PTK) activities that are important in
cell survival and proliferation [25,26,27].
Despite such promising in vitro anticancer data, recent in vivo
studies have reported contradictory results regarding genistein’s
effects on metastasis. Studies using TRAMP and PC-3 animal
models have shown that genistein unexpectedly increased
metastasis [28,29], while another study utilizing a PC-3M in vivo
model showed the opposite effect [30]. These reports in
combination with inconclusive preliminary results from phase II
clinical trials [31,32] suggest a need for closer examination of the
effects of genistein in vivo using models that are more clinically
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relevant than other conventional in vivo models that rely on usage
of cell lines.
In our study, we have utilized a subrenal xenograft technique
employing a low passage of patient-derived PCa specimen in non-
obese diabetic, severe combined immune-deficient (NOD-SCID)
mice. The human cancer xenografts faithfully preserve the
histopathological and genotypical characteristics of the original
clinical sample [33,34]. Using our patient-derived PCa xenograft
system, we have found that genistein at pharmacological dosage
increases cell proliferation, decreases apoptosis and promotes
metastasis in an advanced human PCa. Such tumor-promoting
effects of genistein are associated with increased phosphorylation
of EGFR and Src tyrosine kinases.
Methods
1. Materials and animals
The LTL163a tumor line (www.livingtumorlab.com) is derived
from a high-grade prostate cancer sample obtained from a patient,
and the xenograft tumor transplant line was developed from this
clinical tissue sample as previously described [33,34]. Written
consent was obtained from the patient as well as ethics approval
from University of British Columbia-British Columbia Cancer
Agency Research Ethics Board (UBC BCCA REB), Vancouver,
Canada. Animal care and experiments were carried out in
accordance with the guidelines of the Canadian Council of Animal
Care (CCAC), and the use of animals for our experiments was
examined and approved by the Animal Care Committee of
University of British Columbia (permit #: A10-0100).
Briefly, tumor tissue was cut uniformly into multiple small
pieces, 16363 mm, and grafted under the renal capsule of NOD-
SCID male mice that were 6–8 weeks old [33,34]. Two pieces of
tumor per kidney were placed under renal capsule. Host mice
were supplemented with testosterone pellets (10 mg/mouse),
which were prepared with a PARR pellet press (PARR Instrument
Co., Moline, Illinois) and implanted subcutaneously to promote
cell growth. The grafts were grown in the renal site for 60,90
days, harvested, and portions of the grafts were fixed for
histopathological analysis. To develop a tumor transplant line,
harvested tumor grafts exhibiting rapid growth were cut into small
pieces and re-grafted onto the kidney of new hosts. After three
transplant generations, swollen lymph nodes were noted, which
were bisected and histologically examined for metastasis. Once
metastasis was confirmed, fresh lymph node tissues containing
metastatic deposits were re-transplanted onto the kidney to
develop a metastatic tumor line and designated LTL163a.
2. Genistein treatment
In order to study the pharmacological effects of genistein in
metastasis of human prostate cancer, we chose to use LTL163a
metastatic tumor line, which were derived from the 10th transplant
generation. The tumors were cut into 16363 mm pieces and
grafted into eighteen NOD-SCID male mice with each kidney
having one tumor graft (2 grafts/mouse). Testosterone pellets
(10 mg) were implanted subcutaneously as described above in all
animals at the time of grafting to maintain an adequate serum
testosterone level because genistein-treatment has been shown to
decrease serum testosterone levels via the hypothalamic/pituitary/
gonadal axis [35]. Seven days after grafting, the animals were
randomly divided into three groups; control (untreated), low-dose
and high-dose of genistein (purity .99%, LC Laboratories,
Woburn, MA). Mice in the low-dose group were given genistein
dissolved in peanut oil by gavage at 2 mg/day (80 mg/kg body
weight/day). Mice in the high-dose group were given 10 mg/day
(400 mg/kg/day) of genistein. Control mice received 0.1 ml of oil-
vehicle only. All groups were fed the same rodent diet (PicoLab
Rodent Diet 20) and given autoclaved drinking water. Genistein
treatment was started one week after grafting and continued for
three weeks. The grafts were grown on the kidney for a total of 4
weeks. At the end of the 4th week, blood samples and organs
(kidney with tumor grafts, liver, lung, spleen and lymph nodes)
were collected for analyses.
3. Measurement of serum genistein levels
LC-MS (liquid chromatography-mass spectrometry) was used to
measure the serum level of genistein. First, frozen serum samples
were thawed on ice, and 5 ml of 1 mg/ml luteolin in ethanol was
added to 25 ml of serum as an internal standard (IS). Extraction
was carried out by vortexing with 80 ml of acetonitrile and 5 ml of
0.2 M HCl. The extract was clarified by centrifugation for
5 minutes at 20,0006g, and the supernatant collected, diluted 1:1
with distilled water, and centrifuged for another 5 minutes. The
resultant supernatants were analyzed. An Acquity UPLC with a
2.16100 mm BEH 1.7 mM C18 column coupled to a PDA
detector in line with a Quattro Premier XE (Waters, Milford, MA)
was used with water and acetonitrile containing 0.1% formic acid
as mobile phases. A 25–100% acetonitrile gradient from 0.2–
2.0 minutes was used, followed by re-equilibration to starting
conditions for a total run time of 4.5 min. The MS was run at unit
resolution with 3 kV capillary, 120uC and 350uC source and
desolvation temperatures, 50 and 1000 L/hr cone and desolvation
N2 gas flows and Ar collision gas set to 5.0e
23 mbar. M/z 287.89
and 287.153 were used to detect luteolin IS, and m/z 271.91
and 271.153 were used for genistein with cone voltage and
collision energies optimized for each. OD data from 210–600 nm
was collected with the PDA detector and OD260 was also used as
an endpoint. A 5 point linear calibration curve from 1–800 ng/ml
with 218 ng/ml IS was used for quantitation (R2.0.99;
bias,10%). Genistein-glucoronide was presumed to be the most
common form of conjugate, and the levels were estimated from
OD260 data with the assumption that the extinction coefficient is
similar to that of genistein.
4. Histopathology and immunohistochemistry
Harvested tumor grafts were cut in half at the thickest point of
the tumor. One half was fixed in 10% neutral buffered formalin
for histological/immunohistological (IHC) analyses. The other half
was snap-frozen for protein analysis. The fixed tissue was
processed to paraffin and embedded with the midline cut surface
facing down in the paraffin block, so that sections began at the
original cut midline surface. Preparation of paraffin-embedded
tissues and IHC analyses were carried out as previously described
[34]. The primary antibodies used in this study are Ki67 (Dako,
Carpinteria, CA), caspase-3 (Cell Signaling Technology, Danvers,
MA), ERa (Santa Cruz Biotechnology, Santa Cruz, CA), and ERb
(Biogenex Laboratories, San Ramon, CA). All tissue sections were
counter-stained with 5% (w/v) Harris hematoxylin and cover-
slipped with Permount (Fisher/Thermo Scientific, Waltham, MA).
5. Local Invasion and metastasis analyses
To examine metastatic incidence, lung, liver, renal, pancreatic,
lumbar and thoracic lymph nodes were collected from each
mouse. Each of these organs was fixed and processed as above for
IHC analysis. Sections were stained with an anti-human specific
mitochondria antibody (Millipore, Billerica, MA) and screened for
presence of metastatic cells. Images of IHC-stained sections from
each organ were captured using an AxioCam HR CCD mounted
on an Axioplan 2 microscope and Axiovision 3.1 software (Carl
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Zeiss, Toronto, ON), with final magnifications of 6400.
Percentages of animals containing human metastatic cells in either
lumbar or thoracic lymph nodes were calculated. (In renal and
pancreatic lymph nodes, all animals in three groups showed
evidence of human cancer cells regardless of treatment thus
omitted in the calculation.) For lung and liver, the number of
positively stained cells was counted within randomly-selected
microscopic fields per specimen.
6. Cell proliferation and apoptosis analyses
Proliferation index (PI) was assessed by IHC using a human
specific proliferation marker, Ki67. Images of IHC-stained
sections from each graft were captured as above. The mid section
of the graft with the most densely populated human cancer cells
was selected for imaging for all tumors. The numbers of Ki67
positive and negative-human cells were counted within the entire
microscopic field for each graft of all animals and averaged. Based
on the averaged cell count for each treatment group, PI was
calculated as follows: PI (%) = (Ki67 positive cell count/total
human cell count)6100.
Similarly, Apoptotic Index (AI) was calculated from cleaved-
caspase-3 stained IHC sections of tumor grafts. The number of
apoptotic cells per 10,000 human cells was counted for each tumor
graft and averaged. AI was calculated as above.
7. Western blot Analysis
The remaining halves of the harvested tumor tissues were snap-
frozen for protein analysis, from which mouse kidney tissues were
surgically removed using a dissecting microscope prior to freezing.
These frozen tissues were homogenized using a mortar and pestle in
NP-40 lysis buffer (150 mM sodium chloride, 1.0% NP40, and
50 mM Tris-HCl pH 8.0) on ice, centrifuged at 12,000 rpm for
20 minutes at 4 degrees Celsius in a microcentrifuge, and
supernatant was collected. The bicinchoninic acid (BCA) assay
(Thermo Scientific, Waltham, MA) was performed according to the
company’s instructions to measure protein concentration for each
tumor sample, and absorbance was measured at 562 nm. For gel
electrophoresis, protein samples were boiled for 5 minutes, and
20 mg of protein was separated on SDS-PAGE (polyacrylamide gel
electrophoresis) gel and electrotransferred to a PVDF membrane.
The membrane was blocked with 5% bovine serum albumin
(Sigma-Aldrich, St. Louis, MO) or 5% non fat milk in Tris Buffered
Saline (pH 7.4) containing 0.1% Tween 20 (TBST) and incubated
with primary antibodies to alpha-actin, phospho (p)-tyrosine (Santa
Cruz Biotechnology, Santa Cruz, CA), total EGFR, p-EGFR
(tyr1068), p-Src (tyr416) and total Src (Cell Signaling Technology,
Danvers, MA). After primary antibody incubation, the membranes
were washed with TBST and probed with appropriate HRP-
conjugated secondary anti-mouse (Pierce, Rockford, IL) or anti-
rabbit (Fisher/Thermo Scientific, Waltham, MA) antibodies. To
detect proteins of interest, an enhanced chemiluminescence
Western Blotting kit was used (Pierce, Rockford, IL).
8. Statistical Analysis
Metastatic Incidence, comparison of serum levels, PI and AI
were evaluated using a two-tailed unpaired Student’s t-test.
Differences were considered statistically significant if p values
were smaller than 0.05.
Results
Serum level of genistein
To ensure that genistein-treated groups received a pharmaco-
logical dosage of the compound, serum concentration of genistein
was measured using high-performance liquid chromatography-
mass spectrometry (HPLC-MS). Our HPLC-MS analysis showed
that the untreated control group had a very low trace of serum
genistein (0.002 mg/ml), whose most likely source is their chow
(PicoLab Rodent Diet 20, Delta, BC). In comparison, low-dose
and high-dose treated animals had 1.30 mg/ml to 6.63 mg/ml of
free genistein, respectively. In our treated mice, ingested genistein
formed glucuronide conjugates, and only a small portion of the
genistein remained as free aglycones in the blood. The levels of
both free and conjugated genistein were significantly higher in low
(p,0.04) and high dose-treated mice (p,0.0006) than in the
control group (Figure 1).
Tumor growth of patient-derived PCa xenograft after
genistein treatment
Effects of genistein on metastasis of advanced human PCa were
examined using our patient-derived PCa xenograft tumor trans-
plant line, LTL163a, which was developed from a prostatectomy
sample of advanced stage and selected for metastatic activity.
Tumors from the 10th transplant generation of LTL163a tumor line
were cut into uniformly sized pieces (16363 mm) and grown under
kidney capsules (one tumor piece/kidney, two tumor grafts/mouse)
of eighteen male NOD SCID mice supplemented with a 10 mg
subcutaneous testosterone pellet. Seven days after grafting, the host
animals were randomly placed into three treatment groups;
untreated-control, low-dose and high-dose genistein. Oral admin-
istration of genistein or oil (for control group) was continued for
three weeks. At the time of harvest, enlarged kidneys with well-
grown tumors were noted for all three groups. The average volume
of tumors for control, low-dose and high-dose groups are; 650 mm3,
655 mm3 and 670 mm3, respectively. Despite increasing tumor
volume trend for genistein treatment, there was no statistical
Figure 1. Serum levels of genistein measured by LC-MS. For
treatment, six animals in low-dose group were given genistein
dissolved in peanut oil by gavage at 2 mg/day (80 mg/kg body
weight/day). Six mice in the high-dose group were given 10 mg/day
(400 mg/kg/day) of genistein. Five control mice (one died before the
end of treatment) received 0.1 ml of vehicle only. Blood was collected
at the end of the 3-week treatment. Columns: mean serum concentra-
tion of genistein 6 SD.
doi:10.1371/journal.pone.0020034.g001
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significance among the groups. In addition to the upward expansive
tumor growth from the kidney surface, tumors from all three groups
invaded locally into the kidney (data not shown).
Genistein promotes lymph node and secondary organ
metastasis
In order to assess the distant spread of tumor cells, we collected
pancreatic, thoracic, lumbar and renal lymph nodes as well as
internal organs. All groups showed evidence of human cancer cells
in renal and pancreatic lymph nodes regardless of treatment (data
not illustrated). However, in lumbar and thoracic nodes, control
group had no or low incidence of metastasis (0% in lumbar and
17% in thoracic). In contrast, both low- and high-dose genistein
treatments showed higher metastatic incidence in these two nodes
compared to the untreated control group (Figure 2a); (17% for
low-dose and 50% for high-dose in lumbar node. 50% for low-
dose and 83% for high-dose in thoracic node). Similarly, the
numbers of metastatic cancer cells in secondary organs such as
lung and liver were significantly higher in genistein-treated groups
than control (Figure 2b). Although scattered cancer cells were
observed in secondary organs of all mice (Figure 2c), only
genistein-treated mice showed aggregation of cancer cells (.75
cell aggregates) in those organs to form islands/micrometastasis as
shown in Figure 2d. Thus, by several criteria, genistein had a dose-
dependent metastasis promoting effect on LN and secondary
organs in our model.
Figure 2. Genistein increases lymph node and secondary organ metastasis. At the time of harvest, lung, liver and four lymph nodes
including renal, pancreatic, lumbar and thoracic nodes were collected from all animals. Each of these organs was fixed, processed, stained with an
anti-human specific mitochondria antibody and screened for presence of human metastatic cells. Images of IHC-stained sections from each organ
were captured using an AxioCam HR CCD mounted on an Axioplan 2 microscope with final magnifications of 6400. a) Percentages of animals
containing human metastatic cells in either lumbar or thoracic lymph nodes were calculated. In renal and pancreatic lymph nodes, all animals in all
three groups showed evidence of human cancer cells regardless of treatment (data not shown) thus omitted in the calculation. However, genistein-
treated groups showed increased incidence of metastasis in lumbar and thoracic nodes compared to the untreated control group. The metastatic
spread into lumbar and thoracic lymph nodes are presented as mean percentage in mice carrying LTL163A tumor grafts from three groups
(untreated-control, low-dose and high-dose genistein). Black column: metastatic incidence of thoracic lymph node. White column: metastatic incidence
of lumbar lymph node. b) For lung and liver, the number of positively stained cells was counted within randomly-selected microscopic fields. Column:
mean number of invading cancer cells per microscopic field observed in lung and liver of the three groups 6 SD. Results were statistically analyzed
by t-test at the 95% confidence interval. c) Ki67-IHC staining of representative sections of secondary organs (liver and lung) from untreated-control
and genistein-treated mice. Ki67 antibody used in this study is human specific. All magnifications are 6400. d) Ki67-IHC staining of liver from a
genistein-treated animal showing aggregation of invading cancer cells. Red circle indicates a small island/micrometastasis focus containing .75
human cancer cells, which was observed only in genistein-treated mice. Magnification is6400.
doi:10.1371/journal.pone.0020034.g002
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Genistein affects cell proliferation and apoptosis
Because our data showed that genistein promoted spread of
human cancer cells in the mouse hosts, we investigated its effects
on tumor cell proliferation and apoptosis. Immunohistochemistry
using a human-specific Ki67 antibody was performed to measure
the rate of tumor cell proliferation. The result showed strong
positive intensity within tumor grafts of all groups as well as in the
locally invaded region of the mouse kidney (data not shown).
Proliferation index (PI) was measured from the mid-section of
tumor graft area. The comparison between groups revealed that
both low- and high-dose groups had higher PIs (77.3% and 86.1%,
respectively) than untreated control (70.0%), but only in the high-
dose group was significantly different from the untreated control
group (p = 0.004) as shown in Figure 3.
We also investigated whether genistein affected rates of
programmed cell death, apoptosis. Immunohistochemical analysis
with an anti-caspase 3 antibody revealed that tumors in genistein-
treated mice had fewer caspase-3 positive cells than those in the
control group (Figure 4). The control group had the highest
apoptotic index (AI) of 0.18%, while both low- and high-dose
groups had an AI of only 0.07% (p = 0.05: Figure 4a), indicating a
significantly reduced rate of cell death in genistein-treated tumors.
Genistein increases phosphorylation of protein tyrosine
kinases
Previous in vitro studies have shown that genistein modulates
tyrosine signaling pathways by altering kinase activities [25,26,27].
To determine if enhanced metastasis observed in the genistein-
treated mice was linked to altered phosphorylation patterns,
Western blot analysis was performed on tumor-derived protein
lysates using an anti-phosphotyrosine antibody. Immunoblotting
showed that genistein-treated tumors had higher level of
phosphorylation at a 60 KDa protein band relative to the
untreated control group. Interestingly, at longer exposures of the
x-ray film, more intense band patterns were observed for higher
Figure 3. Genistein stimulates tumor cell proliferation. Prolifer-
ation index (PI) was assessed by IHC using a human specific
proliferation marker, Ki67. The numbers of Ki67 positive and negative-
human cells were counted within randomly selected microscopic field
for each tumor graft of all animals and averaged. Proliferation Index (%):
(Ki67 positive cell count/total human cell count)6100.
doi:10.1371/journal.pone.0020034.g003
Figure 4. Genistein affects programmed cell death/apoptosis. Apoptotic Index (AI) was calculated from caspase-3 stained IHC sections of
tumor grafts from all mice. The number of apoptotic cells per 10,000 human cells was counted for each tumor graft and averaged. a) Apoptotic Index
(%) = (Caspase-3 positive cell count/total human cell count)6100. b) Caspase-3 immunohistological staining of tumor grafts from untreated and
treated animals. Red arrows indicate positive/apoptotic cells. All magnifications are6400. Inset is a magnified image of positive cells.
doi:10.1371/journal.pone.0020034.g004
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molecular weight proteins in the genistein-treated group compared
to control (Figure S1). Of particular interest was a band at
170 KDa. Longer exposure revealed bands in the genistein-treated
group while no phosphorylation was observed in the control group
at this particular sized protein.
To investigate further, we performed immunoblotting with
antibodies targeting specific tyrosine kinases. The possible
candidates for the 60 KDa and 170 Kda proteins (arrows in
Figure 5 and Figure S1) are Src and its potential upstream
molecule, epidermal growth factor receptor (EGFR). As shown in
Figure 6a, genistein increased total EGFR protein expression
slightly when compared to control. While almost all untreated
control tumors (except for one) showed very little to no
phosphorylation of this protein, most genistein-treated tumors
showed high band-intensity (Figure 6a). Similarly, Src, a target of
EGFR, showed slight upregulation of total protein expression
compared to the control group. Again, no phosphorylation of Src
was observed in the control group (except one tumor at a longer
exposure), while a significantly higher level of phosphorylation was
observed in the genistein-treated tumor samples (Figure 6b). These
specific EGFR and Src immunoblot band patterns (Figure 6)
confirm the general p-tyrosine staining patterns observed earlier
(Figure 5).
Discussion
Prostate cancer is the second leading cause of cancer-related
deaths in North America. Since the introduction of androgen
ablation therapy by Huggins and Hodges in the 1940’s, hormone
manipulation has been used as the main therapy for advanced
PCa [36]. Despite initial tumor regression following hormonal
therapy, some remaining PCa cells may survive this therapy,
acquire androgen independency and become hormone refractory
[37]. Once the disease progresses to the hormone-refractory state,
there is no effective treatment currently available [38]. Therefore,
a considerable amount of effort has been invested into strategies to
treat advanced PCa. Previous in vitro studies have suggested that
genistein has chemotherapeutic potential on hormone-dependent
cancer cell lines. However, genistein’s in vivo actions have recently
been challenged by contradictory reports [28,29,30,39,40,41,42].
For example, one study reported that genistein inhibited PC3 bone
tumor growth in SCID mice [43], and another showed that
genistein decreased lung metastasis in androgen receptor-negative
PC3-M implanted mice, which were fed genistein-enriched chow
[30]. In contrast, Raffoul et al. found that genistein ingestion lead
to an increase in lymph node metastasis in their PC3 implanted
animal model [29]. In 2009, Touny and Banerjee demonstrated
biphasic effects of genistein using the TRAMP mouse (transgenic
adenocarcinoma mouse prostate) model. Genistein inhibited
poorly differentiated PCa in these mice when incorporated in
their diet before tumor initiation (ie, when the mice were fed
genistein-diet between 4,12 weeks of age). However, if the
genistein-diet was given to the older TRAMP mice at ages of
12,20 weeks, when prostatic intraepithelial neoplasia (PIN) was
already present, it promoted PCa progression and induced lymph
node metastasis [28]. From such data, it can be implied that life-
time moderate consumption of (or early exposure to) genistein is
important in prevention of the disease, but that genistein may not
exhibit chemotherapeutic effects in vivo once PCa has already been
established or progressed to an advanced stage.
To resolve the controversy of genistein’s effects in vivo, we
developed a clinically relevant xenograft model that has been
generated from a patient prostatectomy specimen. The resultant
patient-derived prostate tumor line used in our study, LTL163a,
has been passaged for only 10 generations in immune-deficient
mice and has maintained the original histopathological and
genotypical characteristics of the original clinical sample [33,34].
Our data show that both low and high dose genistein treatments
promote metastasis in this advanced human PCa transplant line.
Although the tumor size was not significantly different between
control and genistein-treated groups after 3 weeks of treatment,
metastatic incidence was greater in genistein-treated vs untreated
controls. The metastatic progression observed in our model was
characterized by increased cell proliferation and decreased
apoptosis. One of the possibilities for the non-significant difference
in tumor size between groups while genistein treatment increased
proliferation is that all tumor grafts regardless of treatment had
reached the maximum outward growth within the renal capsule,
after which point started to invade inwardly into the kidney, then
to LN and to secondary organs.
Figure 5. Effects of genistein on tyrosine phosphorylation. After three-week treatment of genistein, tumors were harvested, and protein was
extracted from six genistein-treated and five untreated-control mice (one of the control mice died during treatment). Western blot analysis was
performed on tumor-derived protein lysates for phosphotyrosine as described in Materials and Methods. The same blot was stained with an anti-
alpha actin antibody to evaluate protein loading. Lanes represent proteins from individual tumors.
doi:10.1371/journal.pone.0020034.g005
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It is intriguing to note that genistein exhibits biphasic effects in
hormone-dependent cancer cell lines, depending on the dosage
[28,44,45]. Studies with breast cancer cell lines have shown that
low-dose genistein (0.1–25 mM) stimulated growth of estrogen-
dependent cells, while high-dose genistein (50–100 mM) inhibited
proliferation [8,44,45,46]. Wang et al. also demonstrated a similar
biphasic effect of genistein in a non-cancerous prostate epithelial
cell line (RWPE cells) [47]. In our study, however, we did not
observe biphasic effects of genistein with the dose range of 80 mg/
kg/day and 400 mg/kg/day. In order for genistein to exhibit
inhibitory effects on advanced PCa in vivo, it may require higher
dose administration.
Genistein has been shown to modulate activities of PTKs
[25,26,27]. PTKs play a central role in regulating cellular
functions such as proliferation, apoptosis, differentiation and cell
survival [48]. PTK activity is, thus, important in the process of
carcinogenesis and metastasis. EGFR is a membrane-associated
tyrosine kinase, and its activity is regulated by ligand-binding and
by interactions with EGFR family member receptors [49]. Once
this molecule is phosphorylated, the activated signal is passed
down through signaling cascades, activating numerous down-
stream molecules, which ultimately affects cell division, prolifer-
ation and cell migration [49]. Abnormal signaling in EGFR-
related pathways leads to uncontrolled cell growth and has been
reported in many solid tumors such as breast, colorectal and head
and neck and pancreatic cancers [49]. Src is a member of a non-
receptor tyrosine kinase located in cytoplasm and is one of the
downstream molecules of EGFR [50,51]. Dysregulation of Src has
been linked to oncogenesis process for many years [52], and it is
also known to play a role in metastasis by modulating cell motility
and invasive abilities in skin, breast and colon cancers [53]. Our
data show that genistein increases phosphorylation levels of EGFR
and Src in an advanced human PCa, which are linked to
enhanced cell proliferation and decreased apoptosis. Although
previous in vitro studies demonstrate that genistein inhibits some
PTK activities and thus impedes cell growth in cultured cells, our
study shows that it increases phosphorylation of EGFR and Src in
vivo, which is in agreement with the results from a phase I clinical
trial that reported a ‘surprising’ increase in protein tyrosine kinase
phosphorylation after oral administration of genistein [54]. As
Figure 6. Effects of genistein on EGFR signaling. a) Genistein increases phosphorylation of EGFR at tyrosine 1068 residue. Below is the
quantification of band intensity for phosphorylated EGFR from protein lysates of 5 untreated control and 6 genistein-treated tumors. Columns: mean
ratio of phosphorylated EGFR/total EGFR protein band intensity 6 SD. b) Genistein affects phosphorylation of Src at tyrosine 416 residue. Activated
Src expression is significantly higher in genistein-treated tumors than that in untreated control. Lanes represent proteins from individual tumors.
doi:10.1371/journal.pone.0020034.g006
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demonstrated here, it is important to note the difference between
studies utilizing cultured cells versus in vivo studies that more
closely mimic clinical cancer [55]. What contributes to this
difference may lie in the dynamic tissue interactions that exist in
the tumor microenvironment unique to in vivo models. For
example, growth factors released by the stroma or systemic
hormonal influence on cells may affect their biology in ways that
cannot be replicated by isolated cancer cells in vitro.
Because of genistein’s preferential binding to ERb [57,58] and
the high and exclusive expression of ERb in our tumor line (no
ERa expression; Figure S2), it can be hypothesized that genistein’s
tumor stimulatory effects observed in this study may be mediated
via ERb activation. It has been shown previously that non-
genomic signaling of ERs can activate PTKs [47,56]. In a non-
tumorigenic prostate epithelial cell line (RWPE-1), which
predominantly expresses ERb, Wang et al. showed that genistein
treatment at low concentrations (0–12.5 mmol/L) increased cell
proliferation and activity of extracellular signal regulated kinase
(ERK) 1/2. They have also shown that anti-estrogen treatment
with ICI 182, 780 inhibited genistein-induced cell proliferation
and activities of ERK1/2 [47]. Another study by Migliaccio et al.
demonstrated that ligand-activated-ERb/androgen receptor (AR)
complex associated with Src, which then activated the Src/Raf-1/
Erk-2 pathway, stimulating cell proliferation in LNCap cells [56].
As demonstrated by the LNCap and RWPE studies [47,56],
genistein-activated ERb may stimulate the EGFR/Src signaling
pathway, which leads to increased proliferation, reduced apoptosis
and tumor progression in our model. More studies are needed to
determine how estrogenic activities of genistein affect tumor
growth in vivo.
In summary, this study has demonstrated that genistein
promotes metastatic activity in advanced PCa. It is possible that
genistein has heterogeneous actions through which promotes
cancer growth and progression in certain subtypes of cancers while
inhibiting other tumors due to differential ERb expressions among
patients. Some PCa cells may have higher expression of ERb than
other cancer cells, favoring the progression of the disease. Future
studies focusing on genistein’s estrogenicity and its interaction with
ERb will help identify the subtypes of cancers whose growth is
promoted or suppressed by genistein, facilitating rational planning
of future clinical trials and minimizing the impact of genistein’s
adverse effects on cancer patients. A better understanding of
genistein’s cancer promoting actions may lead to the discovery of
new therapeutic avenues.
Supporting Information
Figure S1 Effects of genistein on tyrosine phosphorylation.
Western blots were performed for phosphotyrosine: same blot as
Figure 5 except that the X ray film was exposed longer
(30 seconds).
(TIF)
Figure S2 ERa-and ERb-Immunohistological staining of tumor
grafts from untreated-control and genistein-treated mice. All
magnifications are6400.
(TIF)
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